Search Results

Azitra, Inc. today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.

Azitra, Inc. today announced preclinical data from the Company’s platform and pipeline.

Azitra, Inc. today reported financial results for the full year ended December 31, 2023, and provided a business update.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported financial results for the three months ended March 31, 2024, and provided a business update.

Azitra, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. patent No. 11,850,267 covering future potential pipeline candidates for indications including ichthyosis vulgaris, titled “Methods and compositions for treating skin disease with recombinant microorganisms.” Travis Whitfill, Azitra’s COO, co-founder, and inventor of the patent stated, “Securing this patent is crucial for expanding our pipeline.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced the pricing of an underwritten public offering of 16,667,000 shares of common stock.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced preclinical data from the Company’s platform and pipeline.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced it will be presenting promising new preclinical data from its platform built to discover treatments for serious skin diseases at three upcoming scientific and medical conferences.